3-ethoxy-17-methyl-morphinane | 99003-82-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: 3-ethoxy-17-methyl-morphinane
• 英文别名: 3-Aethoxy-17-methyl-morphinan；(1R,9R,10R)-4-ethoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
• CAS: 99003-82-4
• 化学式: C₁₉H₂₇NO
• 分子量: 285.429
• InChiKey: DIWAJQNYTVAWMY-QXAKKESOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  左啡诺 生成 3-ethoxy-17-methyl-morphinane
  参考文献：
  名称：

  氧化吗啡烷。（3. Mitteilung）。光学活性3-氧吗啡烷

  摘要：

  光学显微镜中的3-Oxy-N-烷基-吗啡烷被烧成灰烬，而在ther和Esterübergeführt中则消失了。

  DOI：

  10.1002/hlca.19510340715

文献信息

• [EN] MORPHINAN COMPOUNDS<br/>[FR] COMPOSÉS DU MORPHINANE
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2010033801A1

  公开（公告）日：2010-03-25

  This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

  本发明涉及新型的吗啡喃化合物及其可药用盐。本发明还提供了包含本发明化合物的组合物，以及在使用σ1受体激动剂且具有NMDA拮抗活性的药物治疗方法中使用该组合物来治疗疾病和状况。
• Deuterated morphinane compounds
  申请人：Concert Pharmaceuticals Inc.

  公开号：EP2418211A1

  公开（公告）日：2012-02-15

  This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a a1 receptor agonist that also has NMDA antagonist activity.

  本发明涉及新型吗啡南化合物及其药学上可接受的盐类。本发明还提供了包含本发明化合物的组合物，以及这种组合物在治疗疾病和病症的方法中的用途，这些疾病和病症通过施用同时具有 NMDA 拮抗剂活性的 a1 受体激动剂而得到有益的治疗。
• DEUTERATED MORPHINAN COMPOUNDS
  申请人：Concert Pharmaceuticals Inc.

  公开号：EP3248978A1

  公开（公告）日：2017-11-29

  This invention relates to novel morphinan compounds bearing a deuteromethyl substituent (CD3) and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

  本发明涉及含有氘代甲基取代基（CD3）的新型吗啡烷化合物及其药学上可接受的盐类。本发明还提供了包含本发明化合物的组合物，以及这种组合物在治疗疾病和病症的方法中的用途，这些疾病和病症通过施用同时具有 NMDA 拮抗剂活性的 σ1 受体激动剂而得到有益的治疗。
• Morphinan compounds
  申请人：Concert Pharmaceuticals, Inc.

  公开号：US10022370B2

  公开（公告）日：2018-07-17

  This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

  本发明涉及新型吗啡南化合物及其药学上可接受的盐类。本发明还提供了包含本发明化合物的组合物，以及这种组合物在治疗疾病和病症的方法中的用途，这些疾病和病症通过施用同时具有 NMDA 拮抗剂活性的 σ1 受体激动剂而得到有益的治疗。
• MORPHINAN COMPOUNDS
  申请人：Concert Pharmaceuticals Inc.

  公开号：EP2334678A1

  公开（公告）日：2011-06-22